Anti-carcinogenic effects of a serine protease inhibitor (FOY-305) through the suppression of neutral serine protease activity during chemical hepatocarcinogenesis in rats.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002251:Carbon Tetrachloride / Q000633:toxicity; D010450:Endopeptidases; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology*; D008099:Liver / Q000201:enzymology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000201:enzymology*; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012697:Serine Endopeptidases; D005723:gamma-Glutamyltransferase / Q000032:analysis
D000970:Antineoplastic Agents; D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate; D002251:Carbon Tetrachloride; D005723:gamma-Glutamyltransferase; D010450:Endopeptidases; D012697:Serine Endopeptidases